Roche

Roche

HY 2021 results

Basel, 22 July 2021

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors;
2 legislative and regulatory developments and economic conditions;
3 delay or inability in obtaining regulatory approvals or bringing products to market;
4 fluctuations in currency exchange rates and general financial market conditions;
5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6 increased government pricing pressures;
7 interruptions in production;
8 loss of or inability to obtain adequate protection for intellectual property rights;
9 litigation;
10 loss of key executives or other employees; and
11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com

All mentioned trademarks are legally protected.

Group

Severin Schwan
Chief Executive Officer

HY 2021 performance

Outlook

HY 2021: Strong start into the year

- **Group sales up +8%**
  - **Diagnostics** with >50% sales growth, supported by **strong recovery of base business**
  - **Pharma** back to growth in Q2, **strong performance of new products** (capturing >50% of Pharma sales)
- **Core EPS up +6%**, **Operating Free Cash Flow +71%**
- **Good development of pipeline**
  - Pharma: 12 Phase III trials initiated; 18 NMEs in late stage (pivotal)
  - Diagnostics: Major system launches (cobas and GenMark)
- **Strong news flow over the next 1.5 years**
  - Faricimab and PDS in ophthalmology, Polivy and CD20xCD3 bi-specifics in hematology, AT-527 in SARS-CoV-2, gantenerumab in Alzheimer's disease, Tecentriq in the adjuvant setting in various cancer types, tiragolumab + Tecentriq combo in 4 different cancer types, giredestrant (SERD) in HR+ breast cancer

At constant exchange rates (CER)

Responding quickly and broadly to the pandemic



Overview - not all COVID-19 related developments captured; EUA=emergency use authorization; RUO=Research use only; * through GenMark acquisition

HY 2021: Strong Diagnostics Division driving Group sales growth

	HY 2021 CHFbn	HY 2020 CHFbn	Change in % CHF	Change in % CER
Pharmaceuticals Division	**21.7**	23.2	**-7**	**-3**
Diagnostics Division	**9.0**	6.1	**49**	**51**
Roche Group	**30.7**	29.3	**5**	**8**

CER=Constant Exchange Rates

HY 2021: Group sales growth recovery



At constant exchange rates (CER); * Q2 2020 sales severely impacted by COVID-19 pandemic onset

HY 2021: New products with continued momentum and strong growth in Diagnostics





HY values in reported CHFm, variances in CERm; [1] Pharma New Products: Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluza, Polivy, Rozlytrek, Phesgo, Enspryng, Evrysdi, Ronapreve (casirivimab/imdevimab); [2] Pharma Bx exposed products: Avastin, Herceptin, MabThera/Rituxan

HY 2021: Normalization of healthcare systems ongoing

Pandemic continues to impact business dynamics



Pharmaceuticals

- Some normalization of healthcare systems, not yet back to pre COVID-19 levels
- Biosimilar impact reaching a high level, expected to flatten in H2

Diagnostics

- Routine business growing
- COVID-19 business showing a slowing momentum towards end of Q2 in line with expectations

Growth rates at CER (Constant Exchange Rates)

HY 2021: Good growth of Core EPS

Core operating profit



Core EPS



Operating free cash flow



CER=Constant Exchange Rates

HY 2021 performance

Outlook

Continuing to invest in innovation in Pharma and Diagnostics

Assets in Ph III & registration at all time high



Diagnostics major systems launches

ePlex System ✔

cobas® 5800[1]

cobas® pure ✔

cobas® pro (high throughput) ✔

cobas® pulse[1]

✔ Launched in countries accepting the CE mark

NME=new molecular entity; [1] currently in development and not commercially available

2021 outlook confirmed

Further growing top and bottom line

Group sales growth[1]	• Low- to mid-single digit
Core EPS growth[1]	• Broadly in line with sales growth
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER); based on the current assessment of the COVID-19 impact

Pharmaceuticals Division

Bill Anderson
CEO Roche Pharmaceuticals

HY 2021: Pharmaceuticals Division sales

Sales still impacted by COVID-19 and biosimilars

	HY 2021	HY 2020	Change in %	
	CHFm	CHFm	CHF	CER
Pharmaceuticals Division	**21,671**	**23,202**	**-7**	**-3**
United States	10,802	12,464	-13	-8
Europe	4,485	4,190	7	4
Japan	1,808	1,908	-5	0
International	4,576	4,640	-1	2

CER=Constant Exchange Rates

HY 2021: Pharmaceuticals Division

Continued investments into R&D to drive future growth

	HY 2021 CHFm	HY 2021 % sales
Sales	**21,671**	**100**
Royalties & other op. inc.	1,372	6.3
Cost of sales	-3,882	-17.9
M & D	-2,962	-13.7
R & D	-5,883	-27.1
G & A	-754	-3.5
Core operating profit	**9,562**	**44.1**



-13% in CHF

CER=Constant Exchange Rates

HY 2021: Continued portfolio rejuvenation

*>50% of sales from new products**



Absolute values and growth rates at Constant Exchange Rates (CER); * Erivedge, Perjeta, Kadcyla, Gazyva, Esbriet, Cotellic, Alecensa, Tecentriq, Ocrevus, Hemlibra, Xofluza, Polivy, Rozlytrek, Phesgo, Enspryng, Evrysdi, Ronapreve (casirivimab/imdevimab)

HY 2021: Oncology still impacted by biosimilars & COVID-19



HER2 franchise

- Kadcyla (+19%) with growth in all regions due to adjuvant BC
- Perjeta (+5%) growth cannibalized by Phesgo launch
- Phesgo: Successful launch (CHFm 96) in US and EU ongoing

Avastin franchise

- Biosimilar erosion in all regions

Tecentriq

- Growth (+29%) driven by 1L SCLC, 1L TNBC and 1L HCC

Hematology franchise*

FDA BTD

- Venclexta: 6th BTD for Venclexta + azacitidine in MDS received
- Venclexta: Strong growth in 1L AML; EU approval in 1L AML achieved
- Gazyva (+8%): Growth due to 1L FL and in 1L CLL
- Polivy (+17%): Growth in R/R DLBCL; Ph III (POLARIX) results in 1L DLBCL expected in H2 2021

Alecensa

- Growth (+20%) driven by International

CER=Constant Exchange Rates; 2021 HY Oncology sales: CHF 10.2bn; CER growth -15%; * Venclexta sales booked by AbbVie and therefore not included (FY-2020 sales of USD 1,337m); Polivy in collaboration with Seagen; BC=breast cancer; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; FL=follicular lymphoma; DLBCL=relapsed/refractory diffuse large B cell lymphoma; SCLC=small cell lung cancer; TNBC=triple negative breast cancer; HCC=hepatocellular carcinoma

Tecentriq overview: Growth driven by first-in-class indications

Landmark results in adjuvant NSCLC presented and filed



Tecentriq Q2 update

Lung franchise (NSCLC, SCLC)

- EU: Growth driven by 1L SCLC
- EU: 1L PDL1+ NSCLC (IMpower110) approved

GI franchise (HCC)

- US/EU/Japan: Growth driven by 1L HCC

Outlook 2021

- US/EU/JP: Adjuvant PDL1+ NSCLC (IMpower010) filed (RTOR in the US)

CER=Constant Exchange Rates; NSCLC=non small cell lung cancer; SCLC=small cell lung cancer; HCC=hepatocellular cancer

Hemophilia A franchise: Hemlibra growing strongly

29% US/EU-5 patient share reached



Hemophilia Q2 update

- US/EU: Gaining market share in non-inhibitors despite some COVID-19 impact
- #1 prescribed prophylaxis in the US for people with hemophilia A; >11,500 patients treated globally
- Hemlibra continues to penetrate across all patient types

Outlook 2021

- Further growth expected
- US/EU: Further patient share gains in non-inhibitors

CER=Constant Exchange Rates; US/EU-5 Market share based on the approved patient populations

Immunology franchise remains impacted by COVID-19



Actemra for COVID-19
FDA
Emergency Use Authorization

Immunology Q2 update

Actemra (+12%)

- FDA grants EUA for COVID-19 treatment in hospitalized patients
- Remains leading RA monotherapy in EU-5; shift from IV to SC

Esbriet (+1%)

- COVID-19 impact on new patient starts

Xolair (+3%)

- Remains leader in biologics asthma market; growth in CIU
- Self-injection (home use) approved in US

Outlook 2021

- Ph III (MAJESTY) Gazyva in MN first-patient-in in Q2

CER=Constant Exchange Rates; RA=rheumatoid arthritis; CIU=chronic idiopathic urticaria; MN=membranous nephropathy; IV=intravenous; SC=subcutaneous

MS franchise: Ocrevus total US market share increases to 28%

MS late stage development programs progressing well



Q2 update

- US showing recovery as vaccination roll-out progresses, but COVID-19 impact still felt
- Higher dose Ocrevus: Ph III (MUSETTE) in RMS and Ph III (GAVOTTE) in PPMS recruiting strongly
- Fenebrutinib (BTKi): Ph III programs in RMS (FENhance I/II) and PPMS (FENtrepid) recruiting on track

Outlook 2021

- Continued growth expected
- Ongoing Ocrevus launches in International

CER=Constant Exchange Rates; MS=multiple sclerosis; RMS=relapsing MS; PPMS=primary progressive MS

SMA franchise: Strong US and EU launches

>1,800 US patients (approaching 20% total share) after <11 months

Broad uptake across all patient types in the US

Patients treated with all SMA types
Pattern mirrors disease prevalence:
25% type 1, 48% type 2, 27% type 3

Naive (~1/3) and previously treated (~2/3)
Pts switching from both Spinraza & Zolgensma

Broad range of ages
2 month old infants to 70+ year old adults
>50% of patients are adults

>500 HCPs have prescribed Evrysdi

~4,000 patients treated worldwide between clinical trials, commercial, and compassionate use program

Ph III (RAINBOWFISH) interim results:

CHOP-INTEND scores in presymptomatic babies with SMA (n=5) treated for at least 12 months



- Pre-symptomatic babies treated with Evrysdi for at least 12 months reached near maximum CHOP-INTEND scores by 4–5 months of age
- They were able to sit, stand and walk and achieved motor milestones within the WHO windows for healthy children

* SMA=spinal muscular atrophy; HCP=health care professional

Ophthalmology franchise: PDS and faricimab US filings completed

PDS: New Ph III with 36-week dosing interval initiated

Port delivery system (PDS)



- Ph III (ARCHWAY) data in nAMD show more than 90% of patients were able to go six months between treatments
- Ph III trials in DME (PAGODA) and DR (PAVILION) enrolling rapidly
- Additional Ph III (VELODROME) in nAMD with 36-week dosing interval initiated
- US/EU filing completed; US Q4 approval expected (priority review)

Faricimab (anti-VEGF/Ang-2 biMab)



- Ph III (YOSEMITE & RHINE) results in DME positive with improved anatomic outcomes and 50% of patients being able to extend time between treatments to 16 weeks
- Ph III (LUCERNE & TENAYA) results in nAMD positive with 45% of patients being treated every 16 weeks
- Additional Ph III (BALATON & CAMINO) studies in RVO started
- US joint filing in DME/nAMD completed

nAMD=neovascular age-related macular degeneration; DME=diabetic macular edema; DR=diabetic retinopathy; RVO=retinal vein occlusion

Pharma: Strong short- and mid-term news flow

Diversifying the late stage pipeline & setting new standards of care

12 new Ph III studies initiated in H1

New to Phase III in Q1

- Kadcyla + Tecentriq (KATE 3) in 2L+ HER2+ PDL1+ mBC
- rhPTX-2 (STARSCAPE) in IPF
- faricimab (BALATON & CAMINO) in branch & central RVO
- fenebrutinib in RMS (FENhance 1/2)

New to Phase III in Q2

- giredestrant (IidERA) in ER+ adj. BC
- Kadcyla + Tecentriq (ASTEFANIA) in HER2+ eBC high-risk
- Tecentriq (IMvigor011) in ctDNA+, high-risk MIBC
- Gazyva (MAJESTY) in membranous nephropathy
- AT-527 (MORNINGSKY) in adult pts with SARS-COV-2
- PDS with ranibizumab (Velodrome) in wAMD (36w interval)

Neuroscience · Infectious Diseases · Immunology
Oncology/Hematology · Ophthalmology

Strong news flow ahead (data readout)



NSCLC=non-small cell lung cancer; BC=breast cancer; MIBC=muscle-invasive bladder cancer; wAMD=wet age-related macular degeneration; FL=follicular lymphoma; DLBCL=diffuse large B cell lymphoma; ES-SCLC=extensive stage small cell lung cancer; DME=diabetic macular edema; IA=interim analysis; SCCHN=squamous cell carcinoma of the head and neck; RCC=renal cell carcinoma; HCC=hepatocellular carcinoma; * study run by partner AbbVie

2021: Key late-stage news flow*

	Compound	Indication	Milestone	
Regulatory	**Xofluza**	Healthy patients; High risk patients; Post exposure	EU approval	✓
	Evrysdi	SMA type 1/2/3	EU approval	✓
	faricimab	DME/nAMD	US/EU joint filing (DME+AMD)	✓
	Tecentriq	1L PDL1+ NSCLC	EU approval	✓
	Venclexta + azacitidine	1L unfit AML	EU approval	✓
	Ronapreve	SARS-CoV-2	EU approval	
	PDS ranibizumab	nAMD (continuous delivery)	US/EU filing; US approval	
Phase III / pivotal readouts	**faricimab**	nAMD	Ph III TENAYA/LUCERNE	✓
	Ronapreve	SARS-CoV-2 Outpatient	Ph III Study 2067	✓
	Ronapreve	SARS-CoV-2 Prophylaxis	Ph III Study 2069	✓
	Tecentriq	Adjuvant NSCLC	Ph III IMpower010	✓
	Evrysdi	SMA type 1/2/3 switching study	Ph II JEWELFISH	✓
	mosunetuzumab	3L+ FL	Ph Ib GO29781	
	Polivy + R-CHP	1L DLBCL	Ph III POLARIX	
	glofitamab	3L+ DLBCL	Ph Ib NP30179	
	Tecentriq + chemo	Adjuvant SCCHN	Ph III IMvoke010	**2022**

Additional 2021 news flow:

- **Tominersen:** Ph III GENERATION HD1 stoped dosing
- **Ronapreve:** EMA positive scientific opinion for COVID-19
- **Actemra/RoActemra:** US approval for SSc-ILD
- **Xolair**: US approval prefilled syringe for self-injection
- **Actemra:** US EUA for treatment of COVID-19 in hospitalized adults and children
- **Enspryng:** EU approval in NMOSD
- **AT-527**: Ph2 interim results (viral load reduction) in hospitalized patients

* Outcome studies are event-driven: timelines may change; EUA=Emergency use authorization

Roche Pharma Day
Tuesday, 14 September

Digitalization Event
November tbd

ESG Event
Q4 2021 tbd

ASH
December tbd

Diagnostics Division

Thomas Schinecker
CEO Roche Diagnostics

HY 2021: Diagnostics Division sales

Very strong growth driven by COVID-19 and routine testing

	HY 2021 CHFm	HY 2020 CHFm	Change in % CHF	Change in % CER
Diagnostics Division	**9,042**	**6,079**	**49**	**51**
Core Lab	3,726	2,821	32	34
Molecular Lab	2,216	1,558	42	45
Point of Care	1,616	360	349	349
Diabetes Care	894	832	7	10
Pathology Lab	590	508	16	20

CER=Constant Exchange Rates

Diagnostics Division sales growth by quarter

Accelerated growth of routine testing in H1



COVID-19 sales	Q1: 0.1bn	Q2: 0.6bn	Q3: 0.6bn	Q4: 1.1bn	Q1: 1.2bn	Q2: 1.3bn

[1] Quarterly sales growth excluding COVID-19 sales; Growth rates at Constant Exchange Rates CER (avg full year 2020)

HY 2021: Diagnostics Division regional sales

Very strong growth in all regions



All growth rates at Constant Exchange Rates (CER); [1] Europe, Middle East and Africa

HY 2021: Diagnostics Division highlights

Very strong growth across all businesses



- Immunodiagnostics (+40%)
- Clinical Chemistry (+25%)

- Virology (+60%)
- LightMix Systems (+44%)
- POC Molecular (+318%)

- POC Immunodiagnostics (>2,000%)

- Blood glucose monitoring (+13%)
- Insulin delivery systems (-7%)

- Advanced staining (+20%)
- Companion diagnostics (+15%)

CER=Constant Exchange Rates; POC=point of care; [1] GenMark included as of April 23rd; [2] EMEA=Europe, Middle East and Africa

HY 2021: Diagnostics Division

Core operating profit more than doubled

	HY 2021 CHFm	HY 2021 % sales
Sales	**9,042**	**100**
Royalties & other op. inc.	48	0.5
Cost of sales	-4,355	-48.2
M & D	-1,330	-14.7
R & D	-807	-8.9
G & A	-274	-3.0
Core operating profit	**2,324**	**25.7**



CER=Constant Exchange Rates

SARS-CoV-2 Diagnostics portfolio[1]

Comprehensive portfolio of tests and digital solutions

	Clinical Labs		Near Patient	
Molecular solutions	• **cobas**® SARS-CoV-2	*Launched*	• **cobas**® SARS-CoV-2 & Influenza A/B	*Launched*
	• **cobas**® SARS-CoV-2 Variant set 1	*Launched* [7]	• **cobas**® SARS-CoV-2	*Launched*
	• **cobas**® SARS-CoV-2 & Influenza A/B	*Launched*		
	• TIB MOLBIOL LightMix® Modular SARS-CoV-2	*Launched*		
	• **ePlex**® Respiratory Pathogen Panel 2	*Launched*		
Immunology solutions	• Elecsys® Anti-SARS-CoV-2	*Launched*	• SARS-CoV-2 rapid antibody	*Launched* [3,4]
	• Elecsys® Anti-SARS-CoV-2 S[2]	*Launched* [4]	• SARS-CoV-2 rapid antigen	*Launched* [3,4]
	• Elecsys® SARS-CoV-2 antigen	*Launched* [4]	• SARS-CoV-2 rapid antigen nasal	*Launched* [3,4]
	• Elecsys® IL-6 Test to diagnose cytokine release syndrome	*Launched*	• SARS-CoV-2 rapid antigen nasal self-testing	*Launched* [3,4]
	• Elecsys® IGRA (T-cell response) SARS-CoV-2	*In-development*	• SARS-CoV-2 & Influenza A/B rapid antigen	*In-development* [3,4]
Digital solutions	• Viewics LabOps COVID-19 for efficiency improvements	*Launched*	• NAVIFY Remote Monitor	*Launched* [5]
			• v-TAC[6] digital algorithm for blood-gas	*Launched*
			• iThemba Life COVID-19	*Launched*
			• **cobas**® Infinity POC COVID-19	*Launched*
			• NAVIFY Pass	*Launched*

Newly added

[1] Not all products are available in all countries; [2] Spike protein; [3] External distribution partnership; [4] Not yet approved in the US; [5] US only; [6] v-TAC: venous to arterial conversion; [7] Research use only

Close of GenMark acquisition on April 24th

Focus on global expansion of high-medical value syndromic panels

ePlex System (CE[1] & 510k[2])

- Complementing our portfolio, offering the broadest coverage of infectious organisms and resistance genes
- On market:
  - 2 ePlex Respiratory Pathogen Panels (20 viral & 2 bacterial targets)
  - 3 ePlex Blood Culture Identification Panels (gram positive & negative, fungal panels, each with 15-30 targets)
- In development: Additional panels, e.g. Gastrointestinal (GI)
- Installed base: 800+ instruments

Roche will leverage its expertise in assay development, manufacturing and global market reach

[1] 2016; [2] 2017

Claim extensions for cardiac NT-proBNP and Troponin T

Preventing diseases in 5 new clinical settings



ACS=Acute Coronary Syndrome; CV=Cardiovascular; NT-proBNP=N-terminal pro B-type natriuretic peptide; [1] Annual incidence of chest pain estimated at 1,550 per 100,000 individuals (Ruigomez A et al, Family Practice 2006; 23:167); [2] Weiser TG et al, Lancet. 2008;372:139; [3] World Data Atlas: https://knoema.com/atlas /topics/Demographics/Age/Population-aged-70-years; [4] Groenewegen A et al, Eur J Heart Failure 2020; 22: 1342; [5] Saeedi P et al., Diabetes Res Clin Pract 2019; 157: 107843

Elecsys® Anti-p53 immunoassay received CE mark

Aids in earlier diagnosis of esophageal, colorectal & breast cancers



- Over 2 million deaths in 2020 related to these three cancers[1]
- Between 20-50% of patients with mutated p53 will produce anti-p53 autoantibodies
- Quantitative immunoassay detecting anti-p53 antibodies
- Runs on **cobas® e** series of immunoassay analyzers (installed base >44,000)

[1] Source: Globocan 2020

MMR RxDx Panel received FDA approval

VENTANA preferred partner for companion diagnostics



- >380,000 new cases of endometrial cancer (EC) each year[1]
- First MMR IHC-based companion diagnostic assay
- Enables targeted treatment decisions based on the MMR protein status such as immunotherapy treatment with GSK's JEMPERLI
- EC has the highest rates of MMR deficiency of all tumors (20-40%)[2]
- Universal testing of EC for MMR/MSI is recommended[3]
- Partnered with Merck's KEYTRUDA for dMMR solid tumors CDx[4]

MSH2=MutS Homolog 2; MSH6=MutS Homolog 6; MLH1=MutL Homolog 1; PMS2=Post Meiotic Segregation increased Homolog 2; PCNA=Proliferating cell nuclear antigen; MMR=Mismatch repair; IHC=Immunohistochemistry; MSI=Microsatellite instability; dMMR=deficient mismatch repair; [1] Bray F, Ferlay J, et al, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.21492; [2] Kim SR, Pina A, Albert A, et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol Oncol. 2018:151(1):76-81; [3] NCCN Guidelines Version 1.2020, Endometrial Carcinoma; [4] In development

Roche's first step into Automated Insulin Delivery (AID)

Hybrid-closed loop mode for Accu-Chek Insight insulin pump users

Accu-Chek Insight
Automated delivery of insulin based on algorithm



CGM
Continuous measurement informing algorithm

Self-learning AID Algorithm
Determines the correct dose of insulin (Partnership with Diabeloop)

Roche Diabetes Care is the primary contact[1] for customer support for the entire AID system solution

CGM=Continuous Glucose Monitoring; [1] First level customer support

Key launches 2021

	Area	Product	Description	Market	
Instruments	Core Lab	cobas® pure integrated solutions	Low-to-medium volume SWA	CE	✓
		cobas® pro integrated solutions	New high throughput configurations of the cobas pro instrument	US & CE	✓
	Point of Care	cobas® pulse	Successor of Accu-Chek® Inform II	CE	
	Molecular Lab	cobas® 5800	Fully automated low throughput PCR system	CE	
		AVENIO Edge System	Automated sequencing library preparation and target enrichment instrument	WW	
	Diabetes Care	Accu-Chek Instant	New features for the monitoring system to increase performance and user experience	WW	✓
Tests	Core Lab	Elecsys® SARS-CoV-2 Antigen	Automated laboratory assay intended as an aid in the diagnosis of SARS-CoV-2 infection	US	
		Elecsys® NT-proBNP IU • extensions in Heart Failure • extension for Atrial Fibrillation Elecsys® TnT–hs 3 claim extensions in Coronary Arterial Disease	A set of 5 intended use extensions in the Coronary Arterial Disease, Atrial Fibrillation and Heart Failure Space	CE	✓
	Molecular Lab	AVENIO FoundationOne kit (RUO)	Decentralized kit of the FoundationOne test	WW	
		KAPA HyperPETE kit	New targeted sequencing portfolio using primer extension for small targets	WW	
Digital Solutions	Pathology Lab	uPath 2.0	First IVD release and version of Open API of the clinical pathologist workflow module for NAVIFY Digital Pathology & on-premise uPath	WW	
		RUO Algorithms	Whole slide image analysis algorithms (ER (SP1), Ki-67 (30-9), and PR (1E2))	WW	
	Insights	NAVIFY Oncology 1.0	Modular Oncology decision support solution	WW[1]	
		NAVIFY Pass 1.0	Solution for providers to communicate SARS-CoV-2 rapid antigen test results to a mobile app	US & CE[1]	✓
	Core Lab	Elecsys® GAAD Algorithm	Algorithm for early detection of HCC in patients with chronic liver disease.	CE	
	Diabetes Care	RocheDiabetes RemoteCare	Module within the RocheDiabetes Care Platform enabling remote interactions between HCPs and patients, including a patient dashboard, check-in and chat functionality	WW[1]	
		Accu-Chek SugarView	Meter-free blood glucose testing using a smartphone app and test strips	OUS[1]	

RDCP=Roche Diabetes Care Platform; US=FDA approval; WW=Worldwide; OUS=Outside the US; ROU=Research Use Only; CE=European Conformity; [1] Only a few selected countries

Finance

Alan Hippe
Chief Financial Officer

HY 2021 results

Focus on Cash

Outlook

HY 2021: Highlights

Business

- Sales growth of +8% and Core operating profit up +4%
- Core EPS growth +6%

Cash flow

- Operating Free Cash Flow of CHF 8.1bn, +71% higher due to lower payments related to trade and other accounts payable and lower investment in alliance arrangements and in-licensing
- Net debt down by CHF 1.8bn vs. Jun 30th 2020; higher by CHF 5.1bn vs. Dec 31st 2020 due to dividend payments

Net financial results

- Core net financial result improved by +57% driven by higher gains on equity securities and lower interest expenses (+21%)

IFRS

- Net income +2% driven by the operating results

All growth rates at Constant Exchange Rates (CER)

HY 2021: Group performance

Sales growth of +8% and Core EPS growth of +6%

	HY 2021 CHFm	HY 2020 CHFm	Change in % CHF	Change in % CER
Sales	**30,713**	**29,281**	**5**	**8**
Core operating profit	**11,652**	**11,766**	**-1**	**4**
as % of sales	*37.9*	*40.2*		
Core net income	**9,527**	**9,443**	**1**	**6**
as % of sales	*31.0*	*32.2*		
Core EPS (CHF)	**10.56**	**10.44**	**1**	**6**
IFRS net income	**8,216**	**8,465**	**-3**	**2**
as % of sales	*26.8*	*28.9*		
Operating free cash flow	**8,117**	**5,036**	**61**	**71**
as % of sales	*26.4*	*17.2*		
Free cash flow	**6,038**	**3,274**	**84**	**99**
as % of sales	*19.7*	*11.2*		

CER=Constant Exchange Rates

HY 2021: Core EPS development

Growth driven by gains on product disposals & equity securities



All at CER (Constant Exchange Rates); * Core Operating profit excluding impacts from changes in gains on product disposals; ** Other (net) includes effects from changes in: financial income/expense (excl. equity securities), effective tax rate, non-controlling interest and diluted number of shares

HY 2021: Group operating performance

Core operating profit growth of +4%

	HY 2021 CHFm	HY 2021 abs. CER
Sales	**30,713**	**+2,389**
Royalties & other op. inc.	1,420	+374
Cost of sales	-8,237	-1,294
M & D	-4,292	+91
R & D	-6,690	-1,077
G & A	-1,262	-58
Core operating profit	**11,652**	**+425**



-1% in CHF

CER=Constant Exchange Rates

HY 2021: Royalties and other operating income

Increase driven by higher income from disposal of products



CER=Constant Exchange Rates

HY 2021: Core operating profit and margin



[1] At CER=Constant Exchange Rates

HY 2021: Core net financial result

Improvement driven by higher gains on equity securities & lower interest expenses

CHFm

- Net financial result improved by +57% at CER
- Interest expenses[1] decreased by +21% at CER



CER=Constant Exchange Rates (avg full year 2020); [1] incl. amortisation of debt discount and net gains on interest rate derivatives

HY 2021: Group Core tax rate

Lower effect from the resolution of tax disputes in 2021 (-1%p) compared to 2020 (-2%p)



HY 2021: Non-core and IFRS income

Non-core operating expenses above PY driven by Accutane provision release in 2020 and higher Global restructuring plans

	HY 2020	HY 2021		Change in %	
	CHFm	CHFm	CHFm	CHF	CER
Core operating profit	**11,766**	**11,652**	**-114**	**-1**	**+4**
Global restructuring plans	-253	-511	-258		
Amortisation of intangible assets	-830	-830	0		
Impairment of intangible assets[1]	-342	-165	177		
M&A and alliance transactions	-30	-37	-7		
Legal & Environmental[2]	327	-32	-359		
Total non-core operating items	-1,128	-1,575	-447		
IFRS Operating profit	**10,638**	**10,077**	**-561**	**-5**	**-1**
Total financial result & taxes	-2,173	-1,861	312		
IFRS net income	**8,465**	**8,216**	**-249**	**-3**	**+2**

CER=Constant Exchange Rates; IA=intangible assets; [1] incl. goodwill; [2] incl. pension plan settlements

HY 2021 results

Focus on Cash

Outlook

HY 2021: Strong operating free cash flow and margin



[1] At CER=Constant Exchange Rates

HY 2021: Group Operating Free Cash Flow

Higher than PY (+71%) driven by NWC movement & lower investments in Intangible Assets



CER=Constant Exchange Rates; OP=Operating Profit; NWC=Net Working Capital; PP&E=Property, Plant & Equipment incl. increase of lease liability paid; IA=Intangible Assets

HY 2021: Group net debt up vs. YE 2020

Driven by dividends paid



Net debt 31 Dec 2020	Operating Free Cash Flow	Non-Operating Free Cash Flow	Dividends, M&A and Alliance transactions and other	Net debt 30 June 2021
	Intangible Asset	Equity	M&A	Total
Thereof investments in innovation: 2021	-0.3	0.0	-1.9	-2.2
2020	-1.5	-0.3	-0.7	-2.5

Balance sheet 30 June 2021

Equity ratio at 47% (31 Dec 2020: 46%; 30 June 2020: 43%)



CER=Constant Exchange Rates

HY 2021 results

Focus on Cash

Outlook

Currency impact expected to reduce as 2021 progresses



Assuming the 30 June 2021 exchange rates remain stable until end of 2021, 2021 impact [1] is expected to be (%p):

	Q1	HY	Sep YTD	FY
Sales	-4	-3	-2	-1
Core operating profit		-5		-3
Core EPS		-5		-3

[1] On group growth rates

2021 outlook confirmed

Further growing top and bottom line

Group sales growth[1]	• Low- to mid-single digit
Core EPS growth[1]	• Broadly in line with sales growth
Dividend outlook	• Further increase dividend in Swiss francs

[1] At Constant Exchange Rates (CER); based on the current assessment of the COVID-19 impact

Changes to the development pipeline
Q2 2021 update

New to phase I

2 NMEs:
RG6189 FAP-CD40 – solid tumors
RG6338 NME – metabolic diseases

New to phase II

3 NMEs:
RG6139 PD1xLAG3 – solid tumors
RG7769 PD1xTIM3 – solid tumors
RG7835 IgG-IL2 – autoimmune diseases

1 AI:
RG6058 tiragolumab+Tecentriq – neoadj+adj NSCLC

New to phase III

1 NME:
RG6422 AT-527 – SARS-CoV-2

4 AIs:
RG3502 Kadcyla+Tecentriq – HER2+ eBC high-risk
RG6321 PDS with ranibizumab – wAMD 36-week refill interval
RG7446 Tecentriq – ctDNA+ high-risk MIBC
RG7159 Gazyva – membranous nephropathy

New to registration

1 NME:
RG7716 faricimab – DME

2 AIs:
RG7446 Tecentriq – adj NSCLC
RG7716 faricimab – wAMD

Removed from phase I

5 NMEs:
RG6247 4D-110 - choroideremia
RG6296 BCMA x CD16a – r/r MM
RG7876 selicrelumab combos – solid tumors
4DMT 4D-125 – X-linked retinitis pigmentosa
Chugai NME- hyperphosphatemia

Removed from phase II

1 AI:
RG7601 Venclexta+fulvestrant – 2L HR+ BC

Removed from phase III

1 AI:
RG7440 ipatasertib+fulvestrant+palbociclib – 1L HR+ mBC

Approvals

1 NME approved in EU:
RG6168 Enspryng - NMOSD

2 AIs approved in EU:
RG7446 Tecentriq Dx+ - 1L sq/non-sq NSCLC
RG7601 Venclexta+azacitidine – 1L AML

Status as of July 22, 2021

Roche Group development pipeline

Phase I (39 NMEs + 12 AIs)

RG6007	HLA-A2-WT1 x CD3	AML
RG6026	glofitamab monotherapy and combos	heme tumors
RG6058	tiragolumab combos	heme & solid tumors
RG6076	CD19-4-1BBL	heme tumors
RG6115	TLR7 agonist (4)	HCC
RG6160	cevostamab (FcRH5 x CD3)	r/r MM
RG6171	giredestrant (SERD)	ER+/HER2- BC
RG6180	autogene cevumeran±T	solid tumors
RG6185	belvarafenib (pan-RAF inh)+Cotellic	solid tumors
RG6189	FAP-CD40	solid tumors
RG6194	HER2 x CD3	BC
RG6232	TYRP1 x CD3	metastatic melanoma
RG6234	-	multiple myeloma
RG6279	PD1-IL2v	solid tumors
RG6286	-	colorectal cancer
RG6290	MAGE-A4 ImmTAC	solid tumors
RG6292	CD25 MAb ± T	solid tumors
RG6323	IL15/IL15Ra-Fc	solid tumors
RG6330	KRAS G12C	solid tumors
RG6433	SHP2i	solid tumors
RG7440	ipatasertib + rucaparib	mCRPC, solid tumors
	ipatasertib	prostate cancer, pretreated
RG7446	Morpheus platform	solid tumors
	T + Venclexta	maintenance 1L ES-SCLC
RG7601	Venclexta + AMG176	AML
	Venclexta ± azacitidine	r/r MDS
	Venclexta + gilteritinib	r/r AML
RG7802	cibisatamab ± T	solid tumors
RG7827	FAP-4-1BBL + combos	solid tumors
RG7828	mosunetuzumab monotherapy + combos	heme tumors
CHU	FIXa x FX	haemophilia
CHU	glypican-3 x CD3	solid tumors
CHU	codrituzumab	HCC
CHU	CD137 switch antibody	solid tumors
CHU	-	solid tumors & endometriosis
SQZ	PBMC vaccine	solid tumors
RG6287	-	IBD
RG6418	NLRP3 inh	inflammation
RG6315	-	immunologic disorders
RG6006	Abx MCP	bacterial infections
RG6084	PD-L1 LNA	HBV
RG6338	-	metabolic diseases
RG6091	UBE3A LNA	Angelman syndrome
RG6182	-	neurodegenerative diseases
RG6237	-	neuromuscular disorders
RG7637	-	neurodevelopmental disorders
RG6120	VEGF-Ang2 DutaFab	nAMD
RG6179	-	DME
RG6312	-	geographic atrophy
RG7921	-	nAMD
CHU	PTH1 recep. ago	hypoparathyroidism

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases

Metabolism
Neuroscience
Ophthalmology
Other

RG-No - Roche/Genentech
CHU - Chugai managed
IONIS – IONIS managed

SQZ - SQZ Biotechnology managed
NOV - Novimmune managed

T=Tecentriq

Phase II (25 NMEs + 13 AIs)

RG6058	tiragolumab + T	NSCLC
	tiragolumab + T + chemo	1L non-squamous NSCLC
	tiragolumab + T + chemo	neoadj-adj NSCLC
	tiragolumab + T	cervical cancer
	tiragolumab + T	1L PD-L1+ mSCCHN
RG6139	PD1 x LAG3	solid tumors
RG6171	giredestrant (SERD)	neoadjuvant ER+ BC
	giredestrant (SERD)	2/3L ER+/HER2- mBC
RG6180	autogene cevumeran + pembrolizumab	1L melanoma
RG6354	rhPTX-2 (PRM-151)	myelofibrosis
RG6357	SPK-8011	hemophilia A
RG6358	SPK-8016	hemophilia A with inhibitors to factor VIII
RG7601	Venclexta + carfilzomib	r/r MM t(11;14)
RG7769	PD1 x TIM3	solid tumors
CHU	Oncolytic Type 5 adenovirus	esophageal cancer
RG6173	anti-tryptase	asthma
RG7835	IgG-IL2	autoimmune diseases
RG7880	efmarodocokin alfa	inflammatory diseases
NOV	TLR4 MAb	autoimmune diseases
IONIS	ASO factor B	IgA nephropathy
RG6413+RG6412[1]	casirivimab+imdevimab	SARS-CoV-2 hospitalised
RG7854/RG7907/ RG6346[2]	TLR7 ago(3)/CpAM (2)/siRNA	HBV
RG6359	SPK-3006	Pompe disease
RG7992	FGFR1 x KLB MAb	NASH
RG6100	semorinemab	Alzheimer's
RG6102	brain shuttle gantenerumab	Alzheimer's
RG6356	micro-dystrophin (SRP-9001)	DMD
RG7412	crenezumab	familial Alzheimer's healthy pts
RG7816	GABA Aa5 PAM	ASD
RG7906	ralmitaront	schizophrenia
RG7935	prasinezumab	Parkinson's
RG6147	HtrA1	geographic atrophy
RG6367	SPK-7001	choroideremia
RG7774	-	retinal disease
IONIS	ASO factor B	geographic atrophy

[1]combination contributing as two entities
[2]combination platform

Status as of July 22, 2021

Roche Group development pipeline

Phase III (15 NMEs + 39 AIs)

RG3502	Kadcyla + T	2L+ HER-2+ PD-L1+ mBC
	Kadcyla + T	HER-2+ eBC high-risk
RG6013	Hemlibra	mild to moderate hemophilia A
RG6026**	glofitamab + chemo	2L+ DLBCL
RG6058	tiragolumab + T + chemo	1L SCLC
	tiragolumab + T	1L PD-L1+ NSCLC
	tiragolumab + T	locally advanced esophageal cancer
	tiragolumab + T	stage III unresectable 1L NSCLC
RG6107	crovalimab	PNH
RG6114	inavolisib (mPI3K alpha inh)	1L HR+ mBC
RG6171	giredestrant (SERD)	ER+/HER2- mBC
RG6268	Rozlytrek ROS1+	1L NSCLC
RG7440	ipatasertib + abiraterone	1L CRPC
RG7596	Polivy	1L DLBCL
RG7446	Tecentriq + platinum chemo	NSCLC neoadj
	Tecentriq	NMIBC, high risk
	Tecentriq	RCC adj
	Tecentriq + cabozantinib	advanced RCC
	Tecentriq + cabozantinib	2L NSCLC
	T ± chemo	SCCHN adj
	T + capecitabine or carbo/gem	1L TNBC
	T + paclitaxel	TNBC adj
	T + Avastin	HCC adj
	T ± chemo	1L mUC
	Tecentriq	SC NSCLC
	Tecentriq	ctDNA+ high-risk MIBC
RG7601	Venclexta	r/r MM t(11:14)
	Venclexta + azacitidine	1L MDS
RG7828**	mosunetuzumab + lenalidomide	2L+ FL
RG7853	Alecensa	ALK+ NSCLC adj
RG1569	Actemra	COVID-19 pneumonia
RG3648	Xolair	food allergy
RG6354	rhPTX-2 (PRM-151)	idiopathic pulmonary fibrosis
RG7159	Gazyva	lupus nephritis
	Gazyva	membranous nephropathy
RG7413	etrolizumab	Crohn's
RG6152	Xofluza	influenza, pediatric (0-1 year)
	Xofluza	influenza, pediatric (1-12 years)
	Xofluza	influenza direct transmission
RG6413+ RG6412*	casirivimab+imdevimab	SARS-CoV-2 prophylaxis
	casirivimab+imdevimab	SARS-CoV-2 ambulatory
RG6422	AT-527	SARS-CoV-2
RG1450	gantenerumab	Alzheimer's
RG1594	Ocrevus high dose	RMS & PPMS
RG6042	tominersen	Huntington's
RG7845	fenebrutinib	PPMS
RG7845	fenebrutinib	RMS
RG6321	port delivery system with ranibizumab	DME
	port delivery system with ranibizumab	DR
	port delivery system with ranibizumab	wAMD, 36-week
RG7716	faricimab	BRVO
	faricimab	CRVO

T=Tecentriq
*combination contributing as two entities
** phI safety run-in ongoing

Registration (3 NMEs + 4 AIs)

RG6396	Gavreto (pralsetinib) [1]	RET+ NSCLC
	Gavreto (pralsetinib) [2]	RET+ MTC
RG7446	T + nab-paclitaxel [3]	TNBC neoadj
	Tecentriq	NSCLC adj
RG6321	port delivery system with ranibizumab	wAMD
RG7716	faricimab [4]	DME
	faricimab [4]	wAMD

[1] Approved in US, filed in EU
[2] Approved in US
[3] Filed in EU
[4] FDA acceptance pending

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of July 22, 2021

NME submissions and their additional indications

Projects in phase II and III

2021		2022		2023		2024 and beyond					
RG7828	**mosunetuzumab** 3L+ FL	RG6026	**glofitamab** 3L+ DLBCL	RG6058	**tiragolumab + T** 1L PD-L1+ NSCLC	RG6026	**glofitamab + chemo** 2L DLBCL	RG6180	**autogene cevumeran** 1L melanoma	RG6100	**semorinemab** Alzheimer's
RG6413+ RG6412	**casirivimab+imdevimab** SARS-CoV-2 prophylaxis	RG6058	**tiragolumab + Tecentriq (T)** 1L SCLC	RG6114	**inavolisib** (mPI3K alpha inh) 1L HR+ BC	RG6058	**tiragolumab + T** 1L PD-L1+ cervical ca	RG6354	**rhPTX-2 (PRM-151)** myelofibrosis	RG6102	**brain shuttle gantenerumab** Alzheimer's
RG6413+ RG6412	**casirivimab+imdevimab** SARS-CoV-2 ambulatory	RG6107	**crovalimab** PNH[1]	RG6321	**port delivery system with ranibizumab** DME	RG6058	**tiragolumab + T** locally adv esophageal cancer	RG7769	**PD1xTIM3** solid tumors	RG6356	**micro-dystrophin SRP-9001** DMD
RG6413+ RG6412	**casirivimab+imdevimab** SARS-CoV-2 hospitalised	RG6171	**giredestrant (SERD)** 2L/3L ER+/HER2- mBC	RG6321	**port delivery system with ranibizumab** DR	RG6058	**tiragolumab + T** Stage III unresectable 1L NSCLC	RG7828	**mosunetuzumab + lenalidomide** 2L FL	RG7816	**GABA Aa5 PAM** ASD
RG6321	**port delivery system with ranibizumab** wAMD ✓	RG7440	**ipatasertib + abiraterone** 1L CRPC	RG7716	**faricimab** BRVO/CRVO	RG6058	**tiragolumab + T** 1L non-sq NSCLC	RG6173	**Anti-tryptase** asthma	RG7845	**fenebrutinib** PPMS
RG7716	**faricimab** DME✓	RG7413	**etrolizumab** Crohn's			RG6058	**tiragolumab + T** 1L PD-L1+ mSCCHN	RG6354	**rhPTX-2 (PRM-151)** IPF	RG7845	**fenebrutinib** RMS
RG7716	**faricimab** wAMD✓	RG6422	**AT-527** SARS-CoV-2			RG6058	**tiragolumab+T+/- chemo** neoadj/adj NSCLC	RG7880	**efmarodocokin alfa** (IL22-Fc) inflammatory diseases	RG7906	**ralmitaront** schizophrenia
		RG1450	**gantenerumab** Alzheimer's			RG6139	**PD1xLAG3** solid tumors	RG7907/ RG7854/ RG6346	**TLR7 ago (3)/ CpAM (2) /siRNA** HBV	RG7935	**prasinezumab** Parkinson's
						RG6171	**giredestrant (SERD)** 1L ER+/HER2- mBC	RG7992	**FGFR1 x KLB MAb** NASH	RG6321	**port delivery system with ranibizumab** wAMD, 36-week refill

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
[1] First filing in China

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of July 22, 2021

AI submissions for existing products

Projects in phase II and III

New Molecular Entity (NME) | Immunology | Neuroscience
Additional Indication (AI) | Infectious Diseases | Ophthalmology
Oncology / Hematology | Metabolism | Other

2021

RG6152	**Xofluza** influenza, pediatric (1-12 yrs)
RG1569	**Actemra**[1] COVID-19 pneumonia
RG6013	**Hemlibra** Mild to moderate hemophilia A (EU)
RG6268	**Rozlytrek (BFAST)** 1L NSCLC ROS1+
RG7446	**Tecentriq** NSCLC adj ✓
RG7596	**Polivy** 1L DLBCL

2022

RG7446	**Tecentriq** RCC adj
RG7446	**Tecentriq ± chemo** 1L mUC
RG7853	**Alecensa** ALK+ NSCLC adj

2023

RG6152	**Xofluza** direct transmission
RG6152	**Xofluza** influenza, pediatric (0-1 year)
RG3648	**Xolair** Food allergy
RG7446	**Tecentriq** SC NSCLC
RG7446	**Tecentriq + cabozantinib** 2L NSCLC
RG7446	**Tecentriq + cabozantinib** adv RCC
RG7446	**Tecentriq + Avastin** HCC adj
RG7446	**Tecentriq**[2] NSCLC neo adj
RG7601	**Venclexta** r/r MM t(11:14)
RG7601	**Venclexta + azacitidine** 1L MDS

2024 and beyond

RG3502	**Kadcyla + Tecentriq** 2L+ HER-2+ PD-L1+ mBC
RG3502	**Kadcyla + Tecentriq** HER-2+ eBC high-risk
RG7446	**Tecentriq + paclitaxel** TNBC adj
RG7446	**Tecentriq** High risk NMIBC
RG7446	**Tecentriq + chemo** SCCHN adj
RG7446	**Tecentriq + capecitabine or carbo/gem** TNBC
RG7446	**Tecentriq** ctDNA+ high-risk MIBC
RG7159	**Gazyva** lupus nephritis
RG7159	**Gazyva** membranous nephropathy
RG1594	**Ocrevus** high dose RMS & PPMS

✓ Indicates submission to health authorities has occurred
Unless stated otherwise submissions are planned to occur in US and EU
[1]US FDA Emergency Use Authorization received
[2]filing timeline based on data from interim analysis

Status as of July 22, 2021

Major pending approvals 2021

US		EU		China		Japan-Chugai	
RG6321	**PDS with ranibizumab** wAMD Filed April 2021	**RG6396**	**Gavreto (pralsetinib)** **RET+ NSCLC** Filed May 2020	**RG7446**	**Tecentriq** NSCLC adj Filed June 2021	**RG7716**	**faricimab** DME Filed June 2021
RG7716	**faricimab** DME Filed May 2021	**RG7446**	**Tecentriq + nab-paclitaxel** TNBC neoadj Filed Nov 2020 (non-US)			**RG7716**	**faricimab** wAMD Filed June 2021
RG7716	**faricimab** wAMD Filed May 2021	**RG7446**	**Tecentriq** NSCLC adj Filed June 2021			**RG7446**	**Tecentriq** NSCLC adj Filed July 2021
RG7446	**Tecentriq** NSCLC adj Filed June 2021	**RG6321**	**PDS with ranibizumab** wAMD Filed April 2021				
		RG7716	**faricimab** DME Filed May 2021				
		RG7716	**faricimab** wAMD Filed May 2021				

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

PDS=port delivery system

Status as of July 22, 2021

Major granted approvals 2021

US

RG7853	**Alecensa (BFAST)** 1L NSCLC ALK+ Jan 2021
RG1569	**Actemra** SSc-ILD March 2021
RG3648	**Xolair** Self-injection April 2021

EU

RG6152	**Xofluza** influenza, otherwise healthy Jan 2021
RG6152	**Xofluza** influenza, high risk Jan 2021
RG6152	**Xofluza** post exposure prophylaxis Jan 2021
RG7916	**Evrysdi** SMA March 2021
RG6168	**Enspryng** NMOSD June 2021
RG7446	**Tecentriq** 1L non-sq + sq NSCLC Dx+ May 2021
RG7601	**Venclexta+ azacitidine** 1L AML May 2021

China

RG6152	**Xofluza** influenza, otherwise healthy April 2021
RG6152	**Xofluza** influenza, high risk April 2021
RG6013	**Hemlibra** Hemophilia A April 2021
RG7446	**Tecentriq** 1L non-sq + sq NSCLC Dx+ April 2021
RG6168	**Enspryng** NMOSD April 2021
RG7916	**Evrysdi** SMA May 2021
RG3502	**Kadcyla** 2L HER2+ BC June 2021
RG7159	**Gazyva** 1L FL and r/r FL June 2021
RG7446	**Tecentriq + pemetrexed** 1L non-sq NSCLC June 2021

Japan-Chugai

RG7596	**Polivy** r/r DLBCL March 2021
RG7916	**Evrysdi** SMA June 2021
RG6413+ RG6412	**casirivimab+imdevimab** SARS-CoV-2 July 2021

New Molecular Entity (NME)
Additional Indication (AI)
Oncology / Hematology
Immunology
Infectious Diseases
Metabolism
Neuroscience
Ophthalmology
Other

Status as of July 22, 2021

Doing now what patients need next